Peptides for vaccine development
IW Hamley - ACS Applied Bio Materials, 2022 - ACS Publications
This review discusses peptide epitopes used as antigens in the development of vaccines in
clinical trials as well as future vaccine candidates. It covers peptides used in potential …
clinical trials as well as future vaccine candidates. It covers peptides used in potential …
Development of therapeutic vaccines for the treatment of diseases
Y Tian, D Hu, Y Li, L Yang - Molecular Biomedicine, 2022 - Springer
Vaccines are one of the most effective medical interventions to combat newly emerging and
re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent …
re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent …
The HBV web: An insight into molecular interactomes between the hepatitis B virus and its host en route to hepatocellular carcinoma
A Kar, A Samanta, S Mukherjee… - Journal of Medical …, 2023 - Wiley Online Library
Hepatitis B virus (HBV) is a major aetiology associated with the development and
progression of hepatocellular carcinoma (HCC), the most common primary liver malignancy …
progression of hepatocellular carcinoma (HCC), the most common primary liver malignancy …
Hepatitis-B virus: replication cycle, targets, and antiviral approaches
N Nasser, P Tonnerre, A Mansouri, T Asselah - Current Opinion in Virology, 2023 - Elsevier
Highlights•Hepatitis B is a major cause of HCC.•Current treatment does not lead to a
functional cure.•Many new strategies are aiming to achieve a HBV cure.•Combinations with …
functional cure.•Many new strategies are aiming to achieve a HBV cure.•Combinations with …
HBV vaccines: advances and development
F Mahmood, R Xu, MUN Awan, Y Song, Q Han, X Xia… - Vaccines, 2023 - mdpi.com
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to
liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic …
liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic …
[HTML][HTML] Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells
Abstract Background & Aims Liver diseases resulting from chronic HBV infection are a
significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of …
significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of …
Hepatitis B—Current and emerging therapies
Background The hepatitis B virus (HBV) affects an estimated 290 million individuals
worldwide and is responsible for approximately 900 000 deaths annually, mostly from …
worldwide and is responsible for approximately 900 000 deaths annually, mostly from …
A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments
B Laupèze, V Vassilev, S Badur - Expert Review of …, 2023 - Taylor & Francis
ABSTRACT Introduction Chronic hepatitis B (CHB) is rarely cured using available
treatments. Barriers to cure are: 1) persistence of reservoirs of hepatitis B virus (HBV) …
treatments. Barriers to cure are: 1) persistence of reservoirs of hepatitis B virus (HBV) …
[HTML][HTML] HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
T Cargill, P Cicconi, A Brown, L Holland, B Karanth… - JHEP Reports, 2023 - Elsevier
Abstract Background & Aims Millions of people worldwide are infected chronically with HBV,
which results in significant morbidity and mortality. Therapeutic vaccination is a strategy that …
which results in significant morbidity and mortality. Therapeutic vaccination is a strategy that …
Immunological insights in the treatment of chronic hepatitis B
Highlights•Reducing HBV antigen levels per se may not restore virus-specific T-cell
responses.•Successful CHB therapies may combine antivirals and immune-stimulating …
responses.•Successful CHB therapies may combine antivirals and immune-stimulating …